The QT/QTc Study of TAS-116 in patients with solid tumor

EFFECT OF TAS-116 ON CARDIOVASCULAR SAFETY PARAMETERS IN PATIENTS WITH ADVANCED SOLID TUMORS

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080224077

Enrollment

Registered

2018-10-03

Start date

2019-01-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid tumor

Interventions

investigational material(s) Generic name etc : TAS-116 INN of investigational material : - Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Key inclusion criteria - Provided written informed consent - Histologically or cytologically confirmed solid tumor. - Has a lack of response to conventional therapy or no availability of generally acknowledged standard therapy - Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 - QTcF (QT corrected by Fridericia's correction): 450 msec and under - Women of childbearing potential must have a negative pregnancy test at baseline.

Exclusion criteria

Exclusion criteria: Key exclusion criteria - Has a serious illness or medical condition - Women who are pregnant, breastfeeding

Design outcomes

Primary

Measure	Time frame
safety Safety CTCAE (Ver.4.03)	—

Secondary

Measure	Time frame
efficacy pharmacokinetics Efficacy, Pharmacokinetics RECIST (Ver.1.1)	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026